Literature DB >> 21497040

Strategy to confirm the presence of anti-erythropoietin neutralizing antibodies in human serum.

Sergio Sanchez1, Troy Barger, Lei Zhou, Michael Hale, Daniel Mytych, Shalini Gupta, Steven J Swanson, Francesca Civoli.   

Abstract

Functional cell-based assays are the preferred method to test for the presence of anti-rHuEPO neutralizing antibodies (NAbs). However, due to the unpredictable nature of test serum matrix effects on cell-based assays, confirmatory assays are essential for verifying NAb positive results observed during the course of sample testing. The cell-based assay used for the detection of NAbs described by Wei et al. [1] used 32D-EPOR cells, a murine myeloid cell line transfected with the human EPO receptor (EPOR). The 32D-EPOR cell line responded to either rHuEPO or murine interleukin 3 (mIL-3) with proliferation. NAbs were expected to only inhibit rHuEPO-induced cell proliferation and not mIL-3 induced proliferation. Due to reliance on proliferation, the results from this cell-based assay can be confounded by the presence of non-antibody inhibitory serum factors. This paper describes a strategy for confirming that the inhibition of rHuEPO-induced proliferation in a cell-based assay is only attributable to NAbs. The strategy of antibody depletion uses a resin mixture composed of Protein G Sepharose and Protein L Sepharose (Protein G/L resin) to significantly reduce the concentration of immunoglobulins of IgG, IgM and IgA isotypes from human serum prior to testing in the cell-based assay. If the reduction in immunoglobulins in a serum sample corresponds to a reduction in inhibition of EPO-induced proliferation, it would infer that EPO neutralizing activity is antibody-mediated and not due to non-antibody inhibitory serum factors.
Copyright © 2011 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21497040     DOI: 10.1016/j.jpba.2011.03.029

Source DB:  PubMed          Journal:  J Pharm Biomed Anal        ISSN: 0731-7085            Impact factor:   3.935


  6 in total

1.  Statistical and bioanalytical considerations for establishing a depletion criterion for specificity testing during immunogenicity assessment of a biotherapeutic.

Authors:  R O Driscoll; L Zhou; M Moxness; D Mytych; N Chirmule; V Jawa
Journal:  AAPS J       Date:  2013-08-30       Impact factor: 4.009

2.  Drug Target Interference in Immunogenicity Assays: Recommendations and Mitigation Strategies.

Authors:  Zhandong Don Zhong; Adrienne Clements-Egan; Boris Gorovits; Mauricio Maia; Giane Sumner; Valerie Theobald; Yuling Wu; Manoj Rajadhyaksha
Journal:  AAPS J       Date:  2017-10-23       Impact factor: 4.009

3.  A Neutralizing Antibody Assay Based on a Reporter of Antibody-Dependent Cell-Mediated Cytotoxicity.

Authors:  Yuling Wu; Jia J Li; Hyun Jun Kim; Xu Liu; Weiyi Liu; Ahmad Akhgar; Michael A Bowen; Susan Spitz; Xu-Rong Jiang; Lorin K Roskos; Wendy I White
Journal:  AAPS J       Date:  2015-07-24       Impact factor: 4.009

4.  Development of a method that eliminates false-positive results due to nerve growth factor interference in the assessment of fulranumab immunogenicity.

Authors:  Sheng Dai; Allen Schantz; Adrienne Clements-Egan; Michael Cannon; Gopi Shankar
Journal:  AAPS J       Date:  2014-03-05       Impact factor: 4.009

5.  Confirmatory detection of neutralizing antibodies to AAV gene therapy using a cell-based transduction inhibition assay.

Authors:  Theresa Kasprzyk; Sabrina Triffault; Brian R Long; Stephen J Zoog; Christian Vettermann
Journal:  Mol Ther Methods Clin Dev       Date:  2022-01-07       Impact factor: 6.698

Review 6.  Evaluation of the Humoral Response to Adeno-Associated Virus-Based Gene Therapy Modalities Using Total Antibody Assays.

Authors:  Boris Gorovits; Mitra Azadeh; George Buchlis; Travis Harrison; Mike Havert; Vibha Jawa; Brian Long; Jim McNally; Mark Milton; Robert Nelson; Mark O'Dell; Karen Richards; Christian Vettermann; Bonnie Wu
Journal:  AAPS J       Date:  2021-09-16       Impact factor: 4.009

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.